<DOC>
	<DOCNO>NCT00027859</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Drugs ketoconazole may stop production androgen . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether hormone therapy effective combination chemotherapy treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness hormone therapy combination chemotherapy treat patient prostate cancer previously treat androgen suppression .</brief_summary>
	<brief_title>Hormone Therapy Compared With Combination Chemotherapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time objective progression patient prostate cancer rise prostate-specific antigen ( PSA ) androgen suppression treat second-line hormonal therapy ( ketoconazole hydrocortisone ) v combination chemotherapy ( docetaxel estramustine ) . - Compare time PSA progression correlate time objective progression patient treat regimen . - Compare quality life patient treat regimen . - Compare overall survival patient treat regimen . - Compare natural history progression patient treat regimen . - Identify prognostic indicator clinical outcome immunohistochemical evaluation apoptopic biomarkers patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord prior treatment bisphosphonates ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral ketoconazole three time daily oral hydrocortisone twice daily . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive oral estramustine three time daily day 1-5 docetaxel IV 1 hour day 2 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , day 1 week 9 , 6 month 1 year , annually 10 year begin first non-protocol therapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 590 patient ( 295 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate continuously treat androgen suppression Rising prostatespecific antigen ( PSA ) , define PSA &gt; 5 ng/mL , rise 2 consecutive measurement least 4 week apart Gleason score 7 high and/or seminal vesicle involvement diagnosis Patients previously treat antiandrogen glucocorticoid therapy must meet following criterion : Must show continued rise PSA stop antiandrogen ( flutamide , bicalutamide , nilutamide ) glucocorticoid ( dexamethasone prednisone ) At least 4 week continue rise PSA flutamide nilutamide ( 6 week bicalutamide ) Testosterone le 50 ng/dL Patients undergone surgical castration must continue primary androgen suppression maintain castrate level testosterone No progressive measurable local metastatic disease ( include bone metastasis ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGOT great 2 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.7 mg/dL Cardiovascular : No American Heart Association class III IV heart disease No uncontrolled congestive heart failure No lifethreatening cardiac arrhythmia Other : Fertile patient must use effective contraception No prior malignancy unless curatively treat diseasefree appropriate time period specific cancer No preexist peripheral neuropathy great grade 1 No know hypersensitivity polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 5 year since prior systemic chemotherapy Endocrine therapy : See Disease Characteristics At least 4 week since prior hydrocortisone No prior ketoconazole Radiotherapy : At least 28 day since prior radiotherapy primary site No prior palliative radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : Recovered form prior therapy At least 7 day since prior parenteral antibiotic active infection No concurrent digitalis No concurrent H_2 blocker proton pump inhibitor ( arm I ) Concurrent bisphosphonates allow provide initiated prior study therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>